Frequent STAT3 mutations in CD8+ T cells from patients with pure red cell aplasia

Abstract

Dysregulation of T-cell-mediated immunity is responsible for acquired pure red cell aplasia (PRCA). Although STAT3 mutations are frequently detected in patients with T-cell large granular lymphocytic leukemia (T-LGLL), which is often complicated by PRCA and which is also reported to be associated with acquired aplastic anemia (AA) and myelodysplastic syndrome (MDS), whether STAT3-mutated T cells are involved in the pathophysiology of PRCA and other types of bone marrow failure remains unknown. We performed STAT3 mutation analyses of the peripheral blood mononuclear cells from PRCA patients (n 5 42), AA (n 5 54), AA-paroxysmal nocturnal hemoglobinuria (AA-PNH; n 5 7), and MDS (n 5 21) using an allele-specific polymerase chain reaction and amplicon sequencing. STAT3 mutations were not detected in any of the 82 patients with AA/PNH/MDS but were detected in 43% of the 42 PRCA patients. In all 7 STAT3-mutation-positive patients who were studied, the STAT3 mutations were restricted to sorted CD8+ T cells. The prevalence of STAT3 mutation in idiopathic, thymoma-associated, autoimmune disorder-associated, and T-LGLL-associated PRCA was 33% (5 of 15), 29% (2 of 7), 20% (1 of 5), and 77% (10 of 13), respectively. The STAT3-mutation-positive patients were younger (median age, 63 vs 73 years; P5 .026) and less responsive to cyclosporine (46% [6 of 13] vs 100% [8 of 8]; P5 .0092) in comparison with STAT3-mutation-negative patients. The data suggest that STAT3-mutated CD81 T cells may be closely involved in the selective inhibition of erythroid progenitors in PRCA patients.